CERT vs. DH, TNDM, ACAD, MRUS, ACLX, ENOV, MLTX, OLK, QDEL, and BHC
Should you be buying Certara stock or one of its competitors? The main competitors of Certara include Definitive Healthcare (DH), Tandem Diabetes Care (TNDM), ACADIA Pharmaceuticals (ACAD), Merus (MRUS), Arcellx (ACLX), Enovis (ENOV), MoonLake Immunotherapeutics (MLTX), Olink Holding AB (publ) (OLK), QuidelOrtho (QDEL), and Bausch Health Companies (BHC). These companies are all part of the "medical" sector.
Definitive Healthcare (NASDAQ:DH) and Certara (NASDAQ:CERT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.
98.7% of Definitive Healthcare shares are held by institutional investors. Comparatively, 74.0% of Certara shares are held by institutional investors. 14.8% of Definitive Healthcare shares are held by company insiders. Comparatively, 2.4% of Certara shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Definitive Healthcare had 13 more articles in the media than Certara. MarketBeat recorded 30 mentions for Definitive Healthcare and 17 mentions for Certara. Definitive Healthcare's average media sentiment score of 0.29 beat Certara's score of -0.15 indicating that Certara is being referred to more favorably in the news media.
Definitive Healthcare currently has a consensus target price of $9.94, indicating a potential upside of 92.35%. Certara has a consensus target price of $20.06, indicating a potential upside of 17.60%. Given Certara's higher possible upside, equities analysts plainly believe Definitive Healthcare is more favorable than Certara.
Certara has a net margin of -15.62% compared to Certara's net margin of -80.40%. Definitive Healthcare's return on equity of 4.33% beat Certara's return on equity.
Definitive Healthcare has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Certara has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.
Certara has higher revenue and earnings than Definitive Healthcare. Certara is trading at a lower price-to-earnings ratio than Definitive Healthcare, indicating that it is currently the more affordable of the two stocks.
Certara received 1 more outperform votes than Definitive Healthcare when rated by MarketBeat users. Likewise, 34.92% of users gave Certara an outperform vote while only 30.00% of users gave Definitive Healthcare an outperform vote.
Summary
Certara beats Definitive Healthcare on 13 of the 18 factors compared between the two stocks.
Get Certara News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
